Fominoben is an antitussive agent of the benzanilide class, formerly marketed under the name Noleptan.[2] It binds poorly to the sigma-1 receptor, a receptor activated by many other antitussives.[3] It is reported to have respiratory stimulant activity.[4] Other research has indicated it may be an agonist at the benzodiazepine site of the GABAA receptor.[5] It was introduced in Germany in 1973, in Italy in 1979, and in Japan in 1983.[6]
Adverse effects include appetite suppression, nausea, vomiting, insomnia, irritability, and hallucinations. Rarer side effects include somnolence, dizziness, dry mouth, blurred vision, and urticaria.[7]
^"FOMINOBEN". NCATS Inxight: Drugs. Retrieved March 25, 2021.
^Musacchio JM, Klein M (June 1988). "Dextromethorphan binding sites in the guinea pig brain". Cellular and Molecular Neurobiology. 8 (2): 149–56. doi:10.1007/BF00711241. PMID3044591. S2CID33844132.
^Sasaki T, Sugiyama M, Sasaki H, Suzuki S, Takishima T (1985). "Effects of the antitussive fominoben (PB89) on hypoxia in chronic obstructive lung disease: comparison with dextromethorphan using a double-blind method". The Journal of International Medical Research. 13 (2): 96–101. doi:10.1177/030006058501300204. PMID3158563. S2CID30176251.
^Crawley JN, Blumstein LK, Baldino F (January 1984). "Anxiolytic-like properties of fominoben". European Journal of Pharmacology. 97 (3–4): 277–81. doi:10.1016/0014-2999(84)90460-6. PMID6142823.
^Martín AV (2004). "Tratamiento sintomático de la tos y del resfriado común". Farmacología clínica y terapéutica médica. McGraw-Hill/Interamericana. p. 260. ISBN9788448604271.